{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults with obesity or overweight and a weight-related condition.", "entry_form": "claim", "gradeable_restatement": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults meeting the registered obesity-trial eligibility criteria.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline BMI, age, diabetes status, comorbidity, concurrent medications, verified trial formulation, dose and prespecified follow-up; no retrospective responder exclusions.", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ], "original_claim": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults with obesity or overweight and a weight-related condition.", "restatement_note": "The original obesity/overweight eligibility wording is retained in preregistration. This grammatical restatement describes one baseline-defined adult population (BMI at least30, or at least27 with a weight-related condition), not two rival causal hypotheses. Dose, trial product and registered horizon are unchanged." }, "hypothesis": { "name": "Retatrutide: Clinical Weight Loss and Supply Claims", "central_claim": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults meeting the registered obesity-trial eligibility criteria.", "proposed_mechanism": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults with obesity or overweight and a weight-related condition.", "claimed_scope": "Clinically supervised trial-product retatrutide in adults selected at enrollment for obesity or overweight plus a weight-related condition; registered weight-loss horizon24–72weeks, with newly published80-week results reported separately as longer-horizon corroboration.", "claimed_level": [ "response", "maintenance" ], "is_conjunctive": false, "conjunctive_note": "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed." ], "rubric_fit_note": "No shipped rubric directly covers obesity-drug efficacy. Rubric06 is the nearest metabolic route, with explicit clinical adaptation: a randomized specified drug exposure changing bodyweight and prespecified≥5%responder outcomes is a field-valid clinical sufficiency perturbation. Lifespan extension is not required for this non-lifespan claim. Receptor engagement is not equivalent to receptor-specific human necessity; active-comparator superiority and product equivalence have independent evidence standards. The original v5.3 ladder, caps and verbatim rubric text remain unchanged." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Retatrutide engages GLP-1, GIP and glucagon pathways at administered trial exposures.", "subclaim_type": "mechanism", "scope": "Verified trial formulation, dose, species and measured receptor or metabolic endpoint", "claimed_scope": "Verified trial formulation, dose, species and measured receptor or metabolic endpoint", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Original receptor pharmacology, target engagement and preclinical perturbation", "hsef_level": "Δ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Functional receptor assays and LY3437943 mouse pharmacology support in vivo engagement and cross the first perturbation threshold in that experimental setting. Human trial exposure and pharmacokinetics support plausibility, but receptor-by-receptor occupancy, energy expenditure and necessity at therapeutic human exposures are not directly partitioned. This is not a claim of demonstrated human three-receptor necessity.", "rubric_adaptation": "Assess functional receptor activation, specificity/antagonism or genetic perturbation, exposure and living-system phenotypes. Clinical pharmacokinetics do not prove the contribution of each receptor to patient weight loss." }, { "id": "SC2", "statement": "Retatrutide produces clinically meaningful weight loss compared with control in the registered adult population.", "subclaim_type": "sufficiency", "scope": "Trial-eligible adults with obesity or overweight plus a weight-related condition; 24–72-week endpoints and at least 5% weight-loss responder benchmark", "claimed_scope": "Trial-eligible adults with obesity or overweight plus a weight-related condition; 24–72-week endpoints and at least 5% weight-loss responder benchmark", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Randomized weight outcomes, missingness and tolerability; efficacy population versus estimand separated", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Randomized trials show clinically meaningful weight loss in prespecified adult settings, including the48-week obesity phase2 study and36-week diabetes phase2 study. Low doses do not uniformly exceed placebo, and doses and eligibility remain part of context. Additional40-week diabetes phase3 evidence and80-week TRIUMPH results corroborate the effect but have distinct enrollment/horizon qualifications. Replicated same-modality RCTs raise confidence; comparator studies and secondary analyses do not create independent retatrutide causal lines.", "rubric_adaptation": "The applied clinical phenotype is percent bodyweight change and≥5%responder status under randomized control in baseline-defined eligible adults at24–72weeks. Handle missingness, discontinuation, dose escalation and cointerventions explicitly;80-week reports are additional evidence beyond the registered horizon." }, { "id": "SC3", "statement": "Retatrutide is superior to established GLP-1-based treatment for sustained clinical outcomes.", "subclaim_type": "generalization", "scope": "Direct randomized comparable treatment, dose, population and horizon required; across-trial rankings reported separately", "claimed_scope": "Direct randomized comparable treatment, dose, population and horizon required; across-trial rankings reported separately", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Head-to-head outcomes and withdrawal trajectories", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide1.5mg in its specific diabetes phase2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.", "rubric_adaptation": "The registered clinical superiority threshold requires direct randomized comparable modern active treatment, population, dose and duration. Rodent comparison or indirect between-trial ranking does not satisfy it." }, { "id": "SC4", "statement": "Online research-chemical retatrutide reproduces trial product quality, efficacy and safety.", "subclaim_type": "generalization", "scope": "Product identity, content, sterility, supply route and monitored use specified; unverified vials remain unverified", "claimed_scope": "Product identity, content, sterility, supply route and monitored use specified; unverified vials remain unverified", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Direct analytical testing and product-linked clinical evidence; regulatory status distinct from efficacy", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "No directly examined product-linked retatrutide testing plus clinical evidence establishes that online research vials reproduce trial quality, efficacy and safety. Semaglutide/liraglutide analytical testing and a simulated preparation study identify relevant failure modes but cannot characterize every retatrutide vial. This positive equivalence proposition remains speculative; lack of approval and lack of evidence are not direct measurements of every product.", "rubric_adaptation": "Equivalence requires batch-specific identity/content, contamination, formulation/route and exposure plus product-linked clinical outcomes. Regulatory classification and class-product findings are relevant context, not substitutes." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition.", "aggregation_alternatives": { "weakest_link_would_return": "Α", "primary_subclaim_would_return": "Ε", "scope_matched_would_return": "Ε", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M1", "is_nominal": true, "name": "Supervised retatrutide exposure produces clinical weight loss", "core_claim": "Trial-quality retatrutide changes weight in baseline-defined adult obesity/overweight populations.", "explains_what_nominal_does_not": "Trial-quality retatrutide changes weight in baseline-defined adult obesity/overweight populations.", "strongest_supporting_evidence": [ "Placebo and dulaglutide-controlled retatrutide phase2 studies plus subsequentphase3 evidence demonstrate the drug effect." ], "strongest_contradictory_evidence": [ "Three-receptor human necessity, modern active superiority and every dose/context are not established." ], "hsef_level_for_this_model": "Ε", "rationale": "Placebo and dulaglutide-controlled retatrutide phase2 studies plus subsequentphase3 evidence demonstrate the drug effect. Three-receptor human necessity, modern active superiority and every dose/context are not established." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "GLP1-based appetite suppression produces clinical weight loss", "core_claim": "Single GLP1 receptor agonism can produce meaningful weight loss without triple receptor agonism.", "explains_what_nominal_does_not": "Single GLP1 receptor agonism can produce meaningful weight loss without triple receptor agonism.", "strongest_supporting_evidence": [ "STEP placebo and active/withdrawal trials demonstrate semaglutide efficacy, maintenance sensitivity and dose effects." ], "strongest_contradictory_evidence": [ "This does not show GLP1 alone explains all retatrutide benefit or its complete mechanism." ], "hsef_level_for_this_model": "Ε", "rationale": "STEP placebo and active/withdrawal trials demonstrate semaglutide efficacy, maintenance sensitivity and dose effects. This does not show GLP1 alone explains all retatrutide benefit or its complete mechanism." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "GIP/GLP1 dual agonism produces large clinical weight loss", "core_claim": "Dual agonism can produce comparable-order clinical effects without glucagon agonism.", "explains_what_nominal_does_not": "Dual agonism can produce comparable-order clinical effects without glucagon agonism.", "strongest_supporting_evidence": [ "SURMOUNT placebo, direct active comparison and withdrawal trials demonstrate tirzepatide clinical benefit." ], "strongest_contradictory_evidence": [ "Comparable-order across trials is not equivalence; no direct retatrutide versus dual-agonist comparison was examined." ], "hsef_level_for_this_model": "Ε", "rationale": "SURMOUNT placebo, direct active comparison and withdrawal trials demonstrate tirzepatide clinical benefit. Comparable-order across trials is not equivalence; no direct retatrutide versus dual-agonist comparison was examined." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Energy-intake and behavioral intervention reduce weight without triagonism", "core_claim": "Reduced intake and behavioral intervention provide a non-triple-receptor route to weight reduction.", "explains_what_nominal_does_not": "Reduced intake and behavioral intervention provide a non-triple-receptor route to weight reduction.", "strongest_supporting_evidence": [ "Intensive lifestyle/placebo arms and run-in weight changes in STEP3/SURMOUNT3 show measurable loss before added drug effects." ], "strongest_contradictory_evidence": [ "Bundled behavior intervention and selected run-in cohorts do not isolate each component; trial weight effects exceed placebo rather than being explained away." ], "hsef_level_for_this_model": "Δ", "rationale": "Intensive lifestyle/placebo arms and run-in weight changes in STEP3/SURMOUNT3 show measurable loss before added drug effects. Bundled behavior intervention and selected run-in cohorts do not isolate each component; trial weight effects exceed placebo rather than being explained away." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. The nominal leads because it is the only model directly administering retatrutide; the rivals demonstrate alternative weight-loss routes, not that its effect is an artifact. A modern matched active-comparator and mechanistic partition trial would distinguish incremental benefit and receptor necessity.", "study_separating_rank1_from_rank2": "The nominal leads because it is the only model directly administering retatrutide; the rivals demonstrate alternative weight-loss routes, not that its effect is an artifact. A modern matched active-comparator and mechanistic partition trial would distinguish incremental benefit and receptor necessity.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "37366315", "title": "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.", "citation": "Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2301972", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04881760", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A338-adult randomized placebo trial shows dose-related retatrutide weight loss through48weeks, with high-dose responder rates exceeding the registered5% benchmark.", "what_it_does_not_show": "Placebo efficacy is not superiority to semaglutide or tirzepatide; adverse GI events and heart-rate changes remain relevant.", "confounders_present": [ "Placebo efficacy is not superiority to semaglutide or tirzepatide; adverse GI events and heart-rate changes remain relevant." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 2, "pmid": "40609566", "title": "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.", "citation": "Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00092-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Retatrutide reduces DXA fat mass in a randomized T2D phase2 substudy, with positive higher-dose contrasts.", "what_it_does_not_show": "Only103participants completed treatment and both DXA scans; lean mass is not muscle strength, and this shares NCT04867785 rather than supplying a new trial.", "confounders_present": [ "Only103participants completed treatment and both DXA scans; lean mass is not muscle strength, and this shares NCT04867785 rather than supplying a new trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 3, "pmid": "40916752", "title": "Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.", "citation": "Kanu C, Boye KS, Poon JL et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, obesity & metabolism. 2025.", "doi": "10.1111/dom.70097", "pmcid": "PMC12587234", "url": "https://pubmed.ncbi.nlm.nih.gov/40916752/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40916752/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph2, 4:RESULTS:paragraph0, 4:RESULTS:paragraph2, 4:RESULTS:paragraph5, 4:RESULTS:paragraph7, 4:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized phase2 appetite analysis finds higher-dose hunger and disinhibition reductions and modest eating-inventory correlations with weight change.", "what_it_does_not_show": "Satiety/fullness and aggregate appetite-to-weight correlations are often null; self-report correlations do not isolate receptor mediation; same phase2 trial.", "confounders_present": [ "Satiety/fullness and aggregate appetite-to-weight correlations are often null; self-report correlations do not isolate receptor mediation; same phase2 trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 4, "pmid": "42250575", "title": "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.", "citation": "Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)00967-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT06354660", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "TRANSCEND-T2D-1 randomizes537adults and reports treatment-regimen weight loss of11.5–15.3% versus2.6%placebo at40weeks.", "what_it_does_not_show": "Primary endpoint is HbA1c; entry BMI≥23includes participants outside the registered obesity/overweight scope, so whole-cohort means are corroboration with a population limitation.", "confounders_present": [ "Primary endpoint is HbA1c; entry BMI≥23includes participants outside the registered obesity/overweight scope, so whole-cohort means are corroboration with a population limitation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 5, "pmid": "42810372", "title": "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.", "citation": "Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)01861-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT05929079", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "TRIUMPH-2 shows substantial placebo-adjusted weight loss in1152adults with BMI≥27 and T2D using multiple-imputation treatment-regimen analyses.", "what_it_does_not_show": "The80-week endpoint extends beyond the registered24–72-week horizon; no modern active comparator, and dysesthesia/hypotension/discontinuations qualify safety.", "confounders_present": [ "The80-week endpoint extends beyond the registered24–72-week horizon; no modern active comparator, and dysesthesia/hypotension/discontinuations qualify safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 6, "pmid": "37385280", "title": "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.", "citation": "Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023.", "doi": "10.1016/S0140-6736(23)01053-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized double-dummy phase2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide1.5mg through36weeks.", "what_it_does_not_show": "Dulaglutide1.5mg is not modern obesity-dose semaglutide or tirzepatide; six inadvertent enrollments excluded from efficacy analyses; lower dose weak/null.", "confounders_present": [ "Dulaglutide1.5mg is not modern obesity-dose semaglutide or tirzepatide; six inadvertent enrollments excluded from efficacy analyses; lower dose weak/null." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 7, "pmid": "42135195", "title": "Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.", "citation": "Pearson MJ, Willency JA, Lin Y et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2026.", "doi": "10.1210/clinem/dgag201", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42135195/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42135195/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-PHASE2-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Original phase2 metabolomics secondary analyses detect fatty-acid oxidation and insulin-resistance clusters associated with retatrutide.", "what_it_does_not_show": "Mediation models and metabolic proxies do not establish human receptor-specific energy-expenditure causality; shares both phase2 datasets.", "confounders_present": [ "Mediation models and metabolic proxies do not establish human receptor-specific energy-expenditure causality; shares both phase2 datasets." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "RETAT-NCT04881760", "RETAT-NCT04867785" ] }, { "n": 8, "pmid": "42608321", "title": "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.", "citation": "Ruotolo G, Harris C, Lin Y et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, obesity & metabolism. 2026.", "doi": "10.1111/dom.71200", "pmcid": "PMC13646367", "url": "https://pubmed.ncbi.nlm.nih.gov/42608321/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42608321/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-PHASE2-POOLED", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Material and Methods:paragraph0, 1:Material and Methods:paragraph2, 1:Material and Methods:paragraph3, 2:Results:paragraph0, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Original phase2 post-hoc lipid/lipoprotein analyses show treatment-associated shifts in two populations; inflammation changes differ by diabetes status.", "what_it_does_not_show": "Post-discontinuation/rescue samples excluded; no hard cardiovascular outcomes, and lipid/inflammation changes are not independent new causal trials.", "confounders_present": [ "Post-discontinuation/rescue samples excluded; no hard cardiovascular outcomes, and lipid/inflammation changes are not independent new causal trials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "RETAT-NCT04881760", "RETAT-NCT04867785" ] }, { "n": 9, "pmid": "38976257", "title": "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.", "citation": "Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024.", "doi": "10.1001/jamainternmed.2024.2525", "pmcid": "PMC11231910", "url": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38976257", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Propensity-matched dispensing/EHR cohort associates tirzepatide with greater on-treatment weight loss than semaglutide.", "what_it_does_not_show": "Selection, dosing, discontinuation and missing weight measurements remain; neither arm receives retatrutide.", "confounders_present": [ "Selection, dosing, discontinuation and missing weight measurements remain; neither arm receives retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 10, "pmid": "40537987", "title": "Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.", "citation": "Ciudin A, Johansson E, Zimner-Rapuch S et al. Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2025.", "doi": "10.1111/dom.16508", "pmcid": "PMC12326929", "url": "https://pubmed.ncbi.nlm.nih.gov/40537987/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40537987/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT2-STEP2-ITC", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Bucher indirect reanalysis compares SURMOUNT-2 and STEP2 and estimates larger weight reduction with tirzepatide.", "what_it_does_not_show": "Inter-trial comparability assumptions do not create randomized head-to-head allocation; same underlying studies as40321113; no retatrutide arm.", "confounders_present": [ "Inter-trial comparability assumptions do not create randomized head-to-head allocation; same underlying studies as40321113; no retatrutide arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "SURMOUNT2", "STEP2-NCT03552757" ] }, { "n": 11, "pmid": "40321113", "title": "Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.", "citation": "Hankosky ER, He X, Malik R et al. Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, obesity & metabolism. 2025.", "doi": "10.1111/dom.16401", "pmcid": "PMC12146454", "url": "https://pubmed.ncbi.nlm.nih.gov/40321113/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40321113/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT2-STEP2-ITC", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Original indirect reanalysis estimates larger tirzepatide weight reductions than semaglutide, with sensitivity analyses.", "what_it_does_not_show": "Not an independent RCT despite indexed publication tags; shares SURMOUNT-2 and STEP2 and does not test retatrutide superiority.", "confounders_present": [ "Not an independent RCT despite indexed publication tags; shares SURMOUNT-2 and STEP2 and does not test retatrutide superiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "SURMOUNT2", "STEP2-NCT03552757" ] }, { "n": 12, "pmid": "42434924", "title": "Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.", "citation": "Kitamoto T, Yoshino M, Shingaki T et al. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. Current medical research and opinion. 2026.", "doi": "10.1080/03007995.2026.2695047", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42434924/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42434924/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT5-NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT-5 subgroup with baseline Japanese obesity-disease criteria preserves tirzepatide advantage over semaglutide.", "what_it_does_not_show": "Subset of the same trial, not an extra causal line; global enrollment criteria and no retatrutide limit transfer.", "confounders_present": [ "Subset of the same trial, not an extra causal line; global enrollment criteria and no retatrutide limit transfer." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "41938643", "title": "Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.", "citation": "Cetiner S. Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2026.", "doi": "10.2147/DMSO.S594898", "pmcid": "PMC13050166", "url": "https://pubmed.ncbi.nlm.nih.gov/41938643/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41938643/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41938643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Retrospective obesity cohort associates tirzepatide with larger weight reduction than semaglutide/liraglutide.", "what_it_does_not_show": "Nonrandom treatment allocation and treatment persistence selection; cannot rank retatrutide or measure receptor necessity.", "confounders_present": [ "Nonrandom treatment allocation and treatment persistence selection; cannot rank retatrutide or measure receptor necessity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "32730231", "title": "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.", "citation": "Willard FS, Douros JD, Gabe MB et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight. 2020.", "doi": "10.1172/jci.insight.140532", "pmcid": "PMC7526454", "url": "https://pubmed.ncbi.nlm.nih.gov/32730231/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32730231/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32730231", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Original receptor signaling and primary-islet experiments show imbalanced GIPR/GLP1R engagement and GLP1R signaling bias for tirzepatide.", "what_it_does_not_show": "This dual agonist demonstrates an alternative receptor architecture; occupancy estimates are not measured retatrutide target engagement in patients.", "confounders_present": [ "This dual agonist demonstrates an alternative receptor architecture; occupancy estimates are not measured retatrutide target engagement in patients." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 15, "pmid": "40203836", "title": "Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.", "citation": "Ravussin E, Sanchez-Delgado G, Martin CK et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell metabolism. 2025.", "doi": "10.1016/j.cmet.2025.03.011", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40203836/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40203836/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40203836", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Tirzepatide phase1 human and pair-fed mouse studies find fat oxidation and appetite effects, but metabolic adaptation effects differ between species.", "what_it_does_not_show": "Human lack of adaptation effect challenges simple mouse-to-human energy-expenditure transfer; different drug cannot falsify retatrutide weight efficacy.", "confounders_present": [ "Human lack of adaptation effect challenges simple mouse-to-human energy-expenditure transfer; different drug cannot falsify retatrutide weight efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 16, "pmid": "38878772", "title": "Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.", "citation": "Regmi A, Aihara E, Christe ME et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell metabolism. 2024.", "doi": "10.1016/j.cmet.2024.05.010", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38878772/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38878772/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID38945123" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38878772", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Original human adipocyte/mouse assays show context-dependent GIPR effects on glucose uptake, lipid release and clearance.", "what_it_does_not_show": "Tirzepatide/GIPR agonists, not clinical retatrutide; linked correction PMID38945123 is attached and revised numerical details were not available.", "confounders_present": [ "Tirzepatide/GIPR agonists, not clinical retatrutide; linked correction PMID38945123 is attached and revised numerical details were not available." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "34003802", "title": "GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.", "citation": "Samms RJ, Christe ME, Collins KA et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. The Journal of clinical investigation. 2021.", "doi": "10.1172/JCI146353", "pmcid": "PMC8203452", "url": "https://pubmed.ncbi.nlm.nih.gov/34003802/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34003802/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34003802", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Glp1r-null mice and selective GIP agonism separate a weight-independent insulin-sensitization component of tirzepatide.", "what_it_does_not_show": "Glucose disposal and BCAA changes do not demonstrate human weight loss or the necessity of retatrutide glucagon activity.", "confounders_present": [ "Glucose disposal and BCAA changes do not demonstrate human weight loss or the necessity of retatrutide glucagon activity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "35809773", "title": "Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.", "citation": "Knerr PJ, Mowery SA, Douros JD et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular metabolism. 2022.", "doi": "10.1016/j.molmet.2022.101533", "pmcid": "PMC9305623", "url": "https://pubmed.ncbi.nlm.nih.gov/35809773/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35809773/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35809773", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph9, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Optimized triagonist16 outperforms equimolar tirzepatide in DIO mice and raises indirect-calorimetry energy expenditure with similar intake suppression.", "what_it_does_not_show": "Compound16 is not retatrutide; male-mouse exposures and whole-body calorimetry do not establish clinical superiority or partition every receptor.", "confounders_present": [ "Compound16 is not retatrutide; male-mouse exposures and whole-body calorimetry do not establish clinical superiority or partition every receptor." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "37946085", "title": "Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.", "citation": "Liskiewicz A, Khalil A, Liskiewicz D et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature metabolism. 2023.", "doi": "10.1038/s42255-023-00931-7", "pmcid": "PMC10730394", "url": "https://pubmed.ncbi.nlm.nih.gov/37946085/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37946085/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37946085", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Vgat-Gipr deletion removes enhanced weight/intake reduction from long-acting GIP and a dual coagonist in DIO male mice.", "what_it_does_not_show": "Different peptide and cell-specific developmental knockout do not directly establish retatrutide human mechanism or all GIPR cell populations.", "confounders_present": [ "Different peptide and cell-specific developmental knockout do not directly establish retatrutide human mechanism or all GIPR cell populations." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 20, "pmid": "24174327", "title": "Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.", "citation": "Finan B, Ma T, Ottaway N et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science translational medicine. 2013.", "doi": "10.1126/scitranslmed.3007218", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24174327/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24174327/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24174327", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Original dual-incretin development demonstrates metabolic effects across rodents, primates and early humans.", "what_it_does_not_show": "This alternative GIP/GLP1 architecture shows triple agonism is not necessary for weight benefit; no matched human retatrutide comparison.", "confounders_present": [ "This alternative GIP/GLP1 architecture shows triple agonism is not necessary for weight benefit; no matched human retatrutide comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "37277609", "title": "The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.", "citation": "El K, Douros JD, Willard FS et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature metabolism. 2023.", "doi": "10.1038/s42255-023-00811-0", "pmcid": "PMC10290954", "url": "https://pubmed.ncbi.nlm.nih.gov/37277609/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37277609/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37277609", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "ex vivo", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Human-islet receptor antagonism shows tirzepatide insulin secretion depends on both incretin receptors, while mouse potency favors GLP1R.", "what_it_does_not_show": "Insulin secretion is not clinical bodyweight reduction; species-specific potency cautions against simple receptor transfer to retatrutide.", "confounders_present": [ "Insulin secretion is not clinical bodyweight reduction; species-specific potency cautions against simple receptor transfer to retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "40857106", "title": "Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.", "citation": "McMorrow HE, Cohen AB, Lorch CM et al. Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice. The Journal of clinical investigation. 2025.", "doi": "10.1172/JCI186652", "pmcid": "PMC12578400", "url": "https://pubmed.ncbi.nlm.nih.gov/40857106/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40857106/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40857106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Fiber photometry and incretin perturbations show pharmacological analogs inhibit AgRP hunger neurons, with endogenous GIP specificity.", "what_it_does_not_show": "Neural activity and short-term intake do not alone prove the retatrutide clinical mechanism or contribution of glucagon.", "confounders_present": [ "Neural activity and short-term intake do not alone prove the retatrutide clinical mechanism or contribution of glucagon." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "35217653", "title": "Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.", "citation": "Zhao F, Zhou Q, Cong Z et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nature communications. 2022.", "doi": "10.1038/s41467-022-28683-0", "pmcid": "PMC8881610", "url": "https://pubmed.ncbi.nlm.nih.gov/35217653/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35217653/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35217653", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Cryo-EM structures resolve multiplexed receptor binding by tirzepatide and peptide20.", "what_it_does_not_show": "Reconstituted engineered complexes are not living-patient occupancy or proof that three components jointly cause clinical superiority.", "confounders_present": [ "Reconstituted engineered complexes are not living-patient occupancy or proof that three components jointly cause clinical superiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 24, "pmid": "40924112", "title": "GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice.", "citation": "Schreier PCF, Beyerle P, Boulassel S et al. GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice. Diabetologia. 2025.", "doi": "10.1007/s00125-025-06525-0", "pmcid": "PMC12534261", "url": "https://pubmed.ncbi.nlm.nih.gov/40924112/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40924112/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40924112", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "IUB447 knockout/antagonist assays identify GLP1R–Gαq–TRPM5-centered insulin secretion; individual Gipr/Gcgr removal leaves GSIS enhancement.", "what_it_does_not_show": "Different triagonist and glucose endpoint cannot refute retatrutide weight loss; shows triagonist label need not imply equal receptor necessity for every outcome.", "confounders_present": [ "Different triagonist and glucose endpoint cannot refute retatrutide weight loss; shows triagonist label need not imply equal receptor necessity for every outcome." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "39612941", "title": "Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.", "citation": "Wean J, Kowalsky AH, Laker R et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Molecular metabolism. 2025.", "doi": "10.1016/j.molmet.2024.102074", "pmcid": "PMC11946504", "url": "https://pubmed.ncbi.nlm.nih.gov/39612941/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39612941/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39612941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Whole-body and GABAergic GIPR knockout increase GLP1-alone weight effects while eliminating dual-agonist enhancement and anti-aversion.", "what_it_does_not_show": "Both agonism and removal can yield benefit; cell/agent-specific mechanism, not proof all GIPR strategies act identically.", "confounders_present": [ "Both agonism and removal can yield benefit; cell/agent-specific mechanism, not proof all GIPR strategies act identically." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "36799940", "title": "Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.", "citation": "Malavazos AE, Iacobellis G, Dozio E et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. European journal of preventive cardiology. 2023.", "doi": "10.1093/eurjpc/zwad050", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36799940/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36799940/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36799940", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Original33-patient surgical tissue assays report incretin/glucagon receptor expression in epicardial fat.", "what_it_does_not_show": "Expression and transcript associations are presence evidence, not functional drug engagement, weight causality or cardiovascular protection.", "confounders_present": [ "Expression and transcript associations are presence evidence, not functional drug engagement, weight causality or cardiovascular protection." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "38492844", "title": "Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.", "citation": "Akindehin S, Liskiewicz A, Liskiewicz D et al. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular metabolism. 2024.", "doi": "10.1016/j.molmet.2024.101915", "pmcid": "PMC10973979", "url": "https://pubmed.ncbi.nlm.nih.gov/38492844/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38492844/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38492844", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Lepr-Gipr deletion removes enhanced glycemic effects of dual agonism but leaves bodyweight and food-intake effects intact.", "what_it_does_not_show": "Cell-specific null maps receptor-function boundaries; glucose and weight outcomes are different, and retatrutide was not tested.", "confounders_present": [ "Cell-specific null maps receptor-function boundaries; glucose and weight outcomes are different, and retatrutide was not tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 28, "pmid": "35441470", "title": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.", "citation": "Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022.", "doi": "10.1111/dom.14725", "pmcid": "PMC9542252", "url": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP1 extension reports substantial regain after withdrawal of semaglutide and lifestyle support.", "what_it_does_not_show": "Exploratory selected extension with joint lifestyle withdrawal; same STEP1 trial and different drug, not retatrutide withdrawal proof.", "confounders_present": [ "Exploratory selected extension with joint lifestyle withdrawal; same STEP1 trial and different drug, not retatrutide withdrawal proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "33755728", "title": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.", "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "doi": "10.1001/jama.2021.3224", "pmcid": "PMC7988425", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP4-NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP4 randomized continuation versus withdrawal causally separates semaglutide weight maintenance in run-in tolerators.", "what_it_does_not_show": "Enrollment to randomization selects tolerated exposure; this comparative class result cannot establish retatrutide off-treatment durability.", "confounders_present": [ "Enrollment to randomization selects tolerated exposure; this comparative class result cannot establish retatrutide off-treatment durability." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 30, "pmid": "36200477", "title": "Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.", "citation": "Kosiborod MN, Bhatta M, Davies M et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, obesity & metabolism. 2023.", "doi": "10.1111/dom.14890", "pmcid": "PMC10092593", "url": "https://pubmed.ncbi.nlm.nih.gov/36200477/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36200477/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Original STEP1/4 exploratory analyses report cardiometabolic changes that worsen after semaglutide withdrawal.", "what_it_does_not_show": "Shared study participants and surrogate risk metrics cannot supply independent retatrutide efficacy or cardiovascular benefit.", "confounders_present": [ "Shared study participants and surrogate risk metrics cannot supply independent retatrutide efficacy or cardiovascular benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "STEP1-NCT03548935", "STEP4-NCT03548987" ] }, { "n": 31, "pmid": "37605636", "title": "Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.", "citation": "Wilkinson L, Holst-Hansen T, Laursen PN et al. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring, Md.). 2023.", "doi": "10.1002/oby.23842", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37605636/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37605636/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-4-5-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP1/4/5 post-hoc risk-score analyses track improvements with semaglutide and deterioration after withdrawal.", "what_it_does_not_show": "Estimated10-year risk is not observed10-year diabetes incidence; secondary analysis shares trials and excludes retatrutide.", "confounders_present": [ "Estimated10-year risk is not observed10-year diabetes incidence; secondary analysis shares trials and excludes retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "STEP1-NCT03548935", "STEP4-NCT03548987", "STEP5" ] }, { "n": 32, "pmid": "33567185", "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity.", "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "doi": "10.1056/NEJMoa2032183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP1 randomizes1961adults and demonstrates semaglutide weight loss beyond lifestyle/placebo at68weeks.", "what_it_does_not_show": "Different molecule and trial population; percentages must not be ranked as a randomized retatrutide comparison.", "confounders_present": [ "Different molecule and trial population; percentages must not be ranked as a randomized retatrutide comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "40961952", "title": "Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.", "citation": "Wharton S, Freitas P, Hjelmesæth J et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00226-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40961952/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40961952/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961952", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEPUP directly compares semaglutide7.2mg with2.4mg/placebo and reports additional weight loss plus more dysesthesia.", "what_it_does_not_show": "No retatrutide arm; higher-dose comparator benefits and adverse events change the comparison question.", "confounders_present": [ "No retatrutide arm; higher-dose comparator benefits and adverse events change the comparison question." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "39476339", "title": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.", "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2403664", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39476339", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP9 randomizes407adults with kneeOA/obesity and improves weight and pain with semaglutide.", "what_it_does_not_show": "Disease-specific pain scales and population cannot be directly compared with TRIUMPH subgroup outcomes or establish triple receptor necessity.", "confounders_present": [ "Disease-specific pain scales and population cannot be directly compared with TRIUMPH subgroup outcomes or establish triple receptor necessity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 35, "pmid": "33667417", "title": "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.", "citation": "Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021.", "doi": "10.1016/S0140-6736(21)00213-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP2-NCT03552757", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP2 placebo-controlled diabetes/obesity trial establishes semaglutide weight loss and5%responder benefits.", "what_it_does_not_show": "Diabetes modifies population/estimand, and no retatrutide arm; parent dataset for indirect comparison analyses.", "confounders_present": [ "Diabetes modifies population/estimand, and no retatrutide arm; parent dataset for indirect comparison analyses." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "36216945", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.", "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "doi": "10.1038/s41591-022-02026-4", "pmcid": "PMC9556320", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36216945", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP5 demonstrates sustained semaglutide weight benefit at104weeks.", "what_it_does_not_show": "Longer treatment efficacy is not off-treatment durability or retatrutide efficacy; predominantly White/female participants.", "confounders_present": [ "Longer treatment efficacy is not off-treatment durability or retatrutide efficacy; predominantly White/female participants." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 37, "pmid": "33625476", "title": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.", "citation": "Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.", "doi": "10.1001/jama.2021.1831", "pmcid": "PMC7905697", "url": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33625476", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP3 shows semaglutide adds weight benefit to intensive behavioral therapy and initial low-calorie diet.", "what_it_does_not_show": "Co-intervention differs from other obesity trials, precluding naive cross-trial superiority; no retatrutide arm.", "confounders_present": [ "Co-intervention differs from other obesity trials, precluding naive cross-trial superiority; no retatrutide arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "35015037", "title": "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.", "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "doi": "10.1001/jama.2021.23619", "pmcid": "PMC8753508", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35015037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP8 randomized active-drug comparison establishes greater semaglutide than liraglutide weight loss.", "what_it_does_not_show": "Active comparison is open-label and titration/tolerability rules differ; neither regimen is retatrutide.", "confounders_present": [ "Active comparison is open-label and titration/tolerability rules differ; neither regimen is retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "37622681", "title": "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.", "citation": "Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2306963", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37622681", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP-HFpEF improves symptoms, walk distance and weight with semaglutide in obesity-relatedHFpEF.", "what_it_does_not_show": "Specific heart-failure population and endpoint do not establish retatrutide event prevention or clinical superiority.", "confounders_present": [ "Specific heart-failure population and endpoint do not establish retatrutide event prevention or clinical superiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 40, "pmid": "38587233", "title": "Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.", "citation": "Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2313917", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38587233", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP-HFpEF-DM shows semaglutide weight and functional benefits in obesity-relatedHFpEF withT2D.", "what_it_does_not_show": "Different clinical syndrome and molecule; cannot loan hard cardiac or functional outcomes to retatrutide.", "confounders_present": [ "Different clinical syndrome and molecule; cannot loan hard cardiac or functional outcomes to retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 41, "pmid": "39089293", "title": "Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.", "citation": "McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024.", "doi": "10.1016/S2213-8587(24)00182-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39089293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP10 establishes semaglutide weight reduction and normoglycemia in baseline prediabetes.", "what_it_does_not_show": "Normoglycemia endpoint/duration is not long-term disease prevention or evidence of retatrutide superiority.", "confounders_present": [ "Normoglycemia endpoint/duration is not long-term disease prevention or evidence of retatrutide superiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "40961953", "title": "Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.", "citation": "Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00225-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID41932351" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961953", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEPUP-T2D shows semaglutide7.2mg beats placebo for weight loss, with more dysesthesia.", "what_it_does_not_show": "No retatrutide arm and linked erratum PMID41932351 limits unaudited detailed numerics.", "confounders_present": [ "No retatrutide arm and linked erratum PMID41932351 limits unaudited detailed numerics." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "34514682", "title": "Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.", "citation": "Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022.", "doi": "10.1111/dom.14551", "pmcid": "PMC9293236", "url": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-2-3-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP1–4 secondary analyses find semaglutide weight loss both with and without GI events; mediation estimates little GI-mediated loss.", "what_it_does_not_show": "GI mediation is model-dependent, not randomized nausea separation; shared parent trials and not retatrutide.", "confounders_present": [ "GI mediation is model-dependent, not randomized nausea separation; shared parent trials and not retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "STEP1-NCT03548935", "STEP2-NCT03552757", "STEP3", "STEP4-NCT03548987" ] }, { "n": 44, "pmid": "39536238", "title": "Tirzepatide for Obesity Treatment and Diabetes Prevention.", "citation": "Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2410819", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT1-NCT04184622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT1 extended randomized treatment reports sustained tirzepatide weight loss and lower observed diabetes progression over176weeks.", "what_it_does_not_show": "Same SURMOUNT1 study as72-week report, restricted baseline prediabetes cohort; benefit cannot be transferred to retatrutide.", "confounders_present": [ "Same SURMOUNT1 study as72-week report, restricted baseline prediabetes cohort; benefit cannot be transferred to retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 45, "pmid": "35658024", "title": "Tirzepatide Once Weekly for the Treatment of Obesity.", "citation": "Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022.", "doi": "10.1056/NEJMoa2206038", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT1-NCT04184622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT1 establishes tirzepatide weight loss and responder benefits beyond placebo at72weeks.", "what_it_does_not_show": "No retatrutide and different dose schedules, estimands and populations from triple-agonist trials.", "confounders_present": [ "No retatrutide and different dose schedules, estimands and populations from triple-agonist trials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "38078870", "title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.", "citation": "Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.", "doi": "10.1001/jama.2023.24945", "pmcid": "PMC10714284", "url": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT4-NCT04660643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT4 randomized withdrawal shows weight regain after switch to placebo and maintenance with continued tirzepatide.", "what_it_does_not_show": "Open-label run-in selects completers/tolerators, and class withdrawal does not establish retatrutide withdrawal dynamics.", "confounders_present": [ "Open-label run-in selects completers/tolerators, and class withdrawal does not establish retatrutide withdrawal dynamics." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 47, "pmid": "40353578", "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.", "citation": "Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2416394", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT5-NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT5 directly randomizes tirzepatide versus semaglutide and demonstrates greater tirzepatide weight reduction at72weeks.", "what_it_does_not_show": "Open-label active comparison and dose tolerability differ; this establishes their relationship, not retatrutide superiority.", "confounders_present": [ "Open-label active comparison and dose tolerability differ; this establishes their relationship, not retatrutide superiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 48, "pmid": "38819983", "title": "Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.", "citation": "Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.", "doi": "10.1001/jama.2024.9217", "pmcid": "PMC11337071", "url": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38913535" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38819983", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT-CN demonstrates placebo-controlled tirzepatide weight loss in Chinese adults at52weeks.", "what_it_does_not_show": "Different drug/regionalBMI criteria, and linked erratum PMID38913535 attaches to parent not separate evidence.", "confounders_present": [ "Different drug/regionalBMI criteria, and linked erratum PMID38913535 attaches to parent not separate evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "42119587", "title": "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.", "citation": "Horn DB, Aronne LJ, Wharton S et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)00656-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42119587/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42119587/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID42242249" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42119587", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT-MAINTAIN randomizes continued/reduced-dose tirzepatide versus withdrawal and finds maintenance advantages.", "what_it_does_not_show": "Rescue after substantial regain and modified estimand complicate raw comparisons; linked erratum PMID42242249; not retatrutide.", "confounders_present": [ "Rescue after substantial regain and modified estimand complicate raw comparisons; linked erratum PMID42242249; not retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "37840095", "title": "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.", "citation": "Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023.", "doi": "10.1038/s41591-023-02597-w", "pmcid": "PMC10667099", "url": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38409593" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37840095", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT3 shows tirzepatide adds further loss after a successful intensive lifestyle run-in.", "what_it_does_not_show": "Baseline-to-randomization responders are prespecified selected cohort, not all entrants; linked correction PMID38409593; no retatrutide.", "confounders_present": [ "Baseline-to-randomization responders are prespecified selected cohort, not all entrants; linked correction PMID38409593; no retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 51, "pmid": "40031941", "title": "Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.", "citation": "Kadowaki T, Kiyosue A, Shingaki T et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(24)00377-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40031941/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40031941/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40031941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SURMOUNT-J shows placebo-controlled tirzepatide weight benefits in Japanese obesity-disease patients.", "what_it_does_not_show": "ModifiedITT excludes a site and nationaleligibility differs; no retatrutide; generalization remains endpoint/population-specific.", "confounders_present": [ "ModifiedITT excludes a site and nationaleligibility differs; no retatrutide; generalization remains endpoint/population-specific." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 52, "pmid": "37690519", "title": "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.", "citation": "Friedrichsen MH, Endahl L, Kreiner FF et al. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. Molecular metabolism. 2023.", "doi": "10.1016/j.molmet.2023.101801", "pmcid": "PMC10568562", "url": "https://pubmed.ncbi.nlm.nih.gov/37690519/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37690519/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID39245214" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37690519", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Original three NN1177 dual-agonist phase1 trials show weight loss but safety signals stop development.", "what_it_does_not_show": "Different peptide and short trials; linked erratum PMID39245214; efficacy alone does not guarantee safety of polyagonism.", "confounders_present": [ "Different peptide and short trials; linked erratum PMID39245214; efficacy alone does not guarantee safety of polyagonism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 53, "pmid": "33475255", "title": "Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.", "citation": "Alba M, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clinical obesity. 2021.", "doi": "10.1111/cob.12432", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33475255/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33475255/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33475255", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "JNJ64565111 dual GLP1/glucagon trial reduces weight versus placebo with greater GI events.", "what_it_does_not_show": "No GIP component yet weight benefit, so triple agonism is not necessary for weight loss in general; different molecule does not rank retatrutide.", "confounders_present": [ "No GIP component yet weight benefit, so triple agonism is not necessary for weight loss in general; different molecule does not rank retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 54, "pmid": "33475251", "title": "Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.", "citation": "Di Prospero NA, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clinical obesity. 2021.", "doi": "10.1111/cob.12433", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33475251/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33475251/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33475251", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "JNJ64565111 lowers weight in T2D/obesity but does not improve HbA1c and raises some glucose measures.", "what_it_does_not_show": "Weight and glycemic benefit separate; short different-agent trial cannot falsify retatrutide's positive clinical results.", "confounders_present": [ "Weight and glycemic benefit separate; short different-agent trial cannot falsify retatrutide's positive clinical results." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 55, "pmid": "42814954", "title": "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.", "citation": "Jastreboff AM, Kaplan LM, Davies MJ et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England journal of medicine. 2026.", "doi": "10.1056/NEJMoa2604169", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42814954/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT05929066", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "TRIUMPH1 randomizes2339adults withoutdiabetes and reports treatment-regimen weight reductions up to25.0% versus3.9%placebo at80weeks.", "what_it_does_not_show": "Beyond registered24–72-week horizon; no active modern comparator; originalabstractcontains an inconsistentOSA sign so that subgroupnumber is not repeated.", "confounders_present": [ "Beyond registered24–72-week horizon; no active modern comparator; originalabstractcontains an inconsistentOSA sign so that subgroupnumber is not repeated." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 56, "pmid": "35985340", "title": "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.", "citation": "Coskun T, Urva S, Roell WC et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism. 2022.", "doi": "10.1016/j.cmet.2022.07.013", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35985340/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35985340/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35985340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals.", "what_it_does_not_show": "Single-dose early human study is not24–72-week efficacy or receptor-component necessity in humans; compound-specific mechanism needs matched counterfactuals.", "confounders_present": [ "Single-dose early human study is not24–72-week efficacy or receptor-component necessity in humans; compound-specific mechanism needs matched counterfactuals." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 57, "pmid": "39509151", "title": "Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.", "citation": "Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024.", "doi": "10.2196/65440", "pmcid": "PMC11582493", "url": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMAGLUTIDE-ONLINE-PURCHASES-2023", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph7, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph21, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Original semaglutide test-purchase study finds mislabeled quantities, measured purity of 7.7-14.37% against a 99% label claim, and endotoxin detected in all three delivered vials, plus nondelivery scams.", "what_it_does_not_show": "The highest-risk small-vendor sample, assay purity interpretation and the upper-bound form of two of the three endotoxin values all matter; this is not retatrutide testing or clinical population incidence.", "confounders_present": [ "The highest-risk small-vendor sample, assay purity interpretation and the upper-bound form of two of the three endotoxin values all matter; this is not retatrutide testing or clinical population incidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 58, "pmid": "39379664", "title": "Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.", "citation": "Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024.", "doi": "10.1007/s11095-024-03771-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39379664", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Analytical follow-on semaglutide/liraglutide comparisons detect altered impurities, content, dissolution and predicted immunogenicity/stability.", "what_it_does_not_show": "In-silico epitopes and quality changes do not demonstrate clinical harms; commercially available follow-ons are not all online retatrutide vials.", "confounders_present": [ "In-silico epitopes and quality changes do not demonstrate clinical harms; commercially available follow-ons are not all online retatrutide vials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 59, "pmid": "42541373", "title": "Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.", "citation": "Sedensky A, Nuzi K, Nolan L et al. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription. Public health reports (Washington, D.C. : 1974). 2026.", "doi": "10.1177/00333549261464876", "pmcid": "PMC13428802", "url": "https://pubmed.ncbi.nlm.nih.gov/42541373/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42541373/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42541373", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Twenty untrained adults performing simulated grey-market semaglutide tasks make dosing/injection-process errors.", "what_it_does_not_show": "Simulation is not actual retatrutide use or measured infection/adverse-event incidence; no instructions reproduced in the review.", "confounders_present": [ "Simulation is not actual retatrutide use or measured infection/adverse-event incidence; no instructions reproduced in the review." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 60, "pmid": "23305646", "title": "Fibroblast growth factor 21 mediates specific glucagon actions.", "citation": "Habegger KM, Stemmer K, Cheng C et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013.", "doi": "10.2337/db12-1116", "pmcid": "PMC3636653", "url": "https://pubmed.ncbi.nlm.nih.gov/23305646/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23305646/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23305646", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:RESEARCH DESIGN AND METHODS:paragraph0, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13, 1:RESULTS:paragraph15, 1:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Glucagon agonist effects on mouse weight/energy expenditure depend on FGF21 deletion, with acute human FGF21 response to glucagon.", "what_it_does_not_show": "Single agonist/mouse knockout and acute biomarker response do not establish human retatrutide glucagon necessity; hyperglycemia can coexist with weight loss.", "confounders_present": [ "Single agonist/mouse knockout and acute biomarker response do not establish human retatrutide glucagon necessity; hyperglycemia can coexist with weight loss." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 65, "verified": 65, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus one-species or in vitro support caps at Γ.", "specific_trigger": "Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide1.5mg in its specific diabetes phase2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Clinically supervised retatrutide causes clinically meaningful weight loss in adults with obesity or overweight and a weight-related condition.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Positive placebo-controlled bodyweight change crosses the adapted clinical threshold forSC2 and is notΓ-capped as a biomarker. Animal/cell receptor results cross only their actual experimental scope; they cannot establish human component necessity or drug-superioritySC3. Lack of online product-linked evidence keepsSC4unestablished without weakening trial efficacy. No weakest-evidence cap is applied to a complementary same-scope convergent set.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID35985340", "gamma_hard_rules_triggered": [ "Human receptor-component partition remains unresolved despite animal functional evidence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Functional receptor assays and LY3437943 mouse pharmacology support in vivo engagement and cross the first perturbation threshold in that experimental setting. Human trial exposure and pharmacokinetics support plausibility, but receptor-by-receptor occupancy, energy expenditure and necessity at therapeutic human exposures are not directly partitioned. This is not a claim of demonstrated human three-receptor necessity.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID37366315, PMID37385280", "gamma_hard_rules_triggered": [ "NoΓhard rule erases positive controlled bodyweight outcomes under the declared clinical adaptation." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Randomized trials show clinically meaningful weight loss in prespecified adult settings, including the48-week obesity phase2 study and36-week diabetes phase2 study. Low doses do not uniformly exceed placebo, and doses and eligibility remain part of context. Additional40-week diabetes phase3 evidence and80-week TRIUMPH results corroborate the effect but have distinct enrollment/horizon qualifications. Replicated same-modality RCTs raise confidence; comparator studies and secondary analyses do not create independent retatrutide causal lines.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Human modern active-comparator superiority is absent; preclinical incremental-efficacy evidence remains atΓ." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide1.5mg in its specific diabetes phase2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No direct retatrutide product-equivalence perturbation was examined." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No directly examined product-linked retatrutide testing plus clinical evidence establishes that online research vials reproduce trial quality, efficacy and safety. Semaglutide/liraglutide analytical testing and a simulated preparation study identify relevant failure modes but cannot characterize every retatrutide vial. This positive equivalence proposition remains speculative; lack of approval and lack of evidence are not direct measurements of every product.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[56] Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "no", "supporting_evidence": [ "[56] Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals." ], "what_would_cross_it": "Partition retatrutide receptor contributions at measured human exposures with matched mechanistic interventions and functional outcomes, not only receptor-binding estimates." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[1] A338-adult randomized placebo trial shows dose-related retatrutide weight loss through48weeks, with high-dose responder rates exceeding the registered5% benchmark.", "[6] Randomized double-dummy phase2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide1.5mg through36weeks." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[1] A338-adult randomized placebo trial shows dose-related retatrutide weight loss through48weeks, with high-dose responder rates exceeding the registered5% benchmark.", "[6] Randomized double-dummy phase2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide1.5mg through36weeks." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "no", "supporting_evidence": [ "[1] A338-adult randomized placebo trial shows dose-related retatrutide weight loss through48weeks, with high-dose responder rates exceeding the registered5% benchmark.", "[6] Randomized double-dummy phase2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide1.5mg through36weeks." ], "what_would_cross_it": "Add a retatrutide-specific withdrawal/rechallenge or distinct validated natural/genetic/exposure line that fails differently from the initiation RCT modality, with comparable eligibility and prespecified weight outcomes. Replication alone improves confidence without adding an independence line." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Publish a direct randomized retatrutide versus obesity-standard semaglutide/tirzepatide comparison with matched estimands and sustained weight/function endpoints." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Independently sample identified retatrutide supply batches, compare validated chemistry/sterility/exposure against trial-quality product and obtain lawful product-linked clinical evidence before claiming equivalence." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Placebo weight trajectory and lower retatrutide doses; active dulaglutide comparison in phase2 T2D.", "Null satiety/fullness and aggregate appetite-weight correlation in the original appetite substudy.", "GIPR cell-specific knockout preserves some weight effects but removes distinct glycemic/anti-aversion effects in comparator models.", "Dual-glucagon coagonistNN1177 weight benefit coexists with safety signals stopping development." ], "note": "Direct retatrutide evidence spans baseline diabetes and non-diabetes, doses and weeks36–48within the registered horizon;80-week phase3 results are reported separately. Some early T2D trials includeBMIbelow the preregistered obesity/overweight threshold, so cohort means are not an exact in-scope subgroup estimate. Lower-dose nulls and appetite endpoint nulls remain in scope. Clinical trial exposure cannot be transferred to unregulated vials, and weight loss does not itself prove mortality or cardiovascular-event benefit." }, "falsification_patterns_met": [ { "pattern": "Broad comparator-superiority and supply-equivalence inference fails its evidentiary test", "evidence": "No reviewed modern retatrutide active-comparator randomization or product-linked retail-equivalence data; positive placebo efficacy is insufficient for either.", "downgrade_applied": false }, { "pattern": "Every receptor/pathway readout does not move together", "evidence": "Appetite satiety/fullness and inflammatory responses include nulls; comparatorcell-specific receptor deletions dissociate glycemia fromweight.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "name": "Therapeutic effect misread as mechanism proof", "evidence": "Drug efficacy does not prove each receptor is necessary inhumans.", "pitfall": "Therapeutic effect misread as mechanism proof", "where": "Drug efficacy does not prove each receptor is necessary inhumans." }, { "name": "Replication confused with independence", "evidence": "Multiple retatrutide RCTs and phase2 secondary reports do not automatically constitute separate causal lines.", "pitfall": "Replication confused with independence", "where": "Multiple retatrutide RCTs and phase2 secondary reports do not automatically constitute separate causal lines." }, { "name": "Selective generalization", "evidence": "Neither model superiority nor class-product analyses establish clinical retatrutide superiority or allvialquality.", "pitfall": "Selective generalization", "where": "Neither model superiority nor class-product analyses establish clinical retatrutide superiority or allvialquality." }, { "name": "Confirmation by biomarker", "evidence": "Lipid and metabolite improvements do not prove hard cardiovascular outcomes.", "pitfall": "Confirmation by biomarker", "where": "Lipid and metabolite improvements do not prove hard cardiovascular outcomes." }, { "name": "Scope fitted to outcome", "evidence": "Eligibility/dose/horizon are retained from enrollment; low-dose/null participants are not removed as nonresponders.", "pitfall": "Scope fitted to outcome", "where": "Eligibility/dose/horizon are retained from enrollment; low-dose/null participants are not removed as nonresponders." } ], "causal_tally_audit": { "tally_claimed_by_document": 3, "tally_after_audit": 3, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 15, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Only direct positive retatrutide study units earnSC2clinical crossing credit; comparator/class studies do not.", "80-week results extend the registered horizon and are not needed to retrospectively redefine it.", "Original pooled reanalyses share parenttrial data; simulated supply tasks and biomarker analyses are not clinical efficacy crosses." ] }, "steelman": { "case_one_rung_higher": "Ζcould be defended from replicated clinical RCTs and mouse receptor perturbations; the positive effect is substantial and consistent. The strongest version would add a retatrutide-specific independent withdrawal or validated mechanistic prediction excluding initiation-trial failure modes.", "case_one_rung_lower": "Δcould be defended because the first trial is unambiguous but exact component mechanism and broader safety are unresolved. That would understate multiple prespecified humancontexts/doses and would confuse missing receptornecessity with absence of the registered drug-sufficiency effect.", "which_rejected": "RejectΖbecause replication and different outcome readouts are not independent causal lines, and class withdrawal cannot be loaned toretatrutide. RejectΔbecause positive constrained clinical causality is established across predefined trialcontexts with interpretable dose/control boundaries. RetainΕModerate.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over72weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity." }, "final_score": { "hsef_level": "Ε", "hsef_descriptor": "Context-specific causality established", "confidence": "Moderate", "confidence_rationale": "60 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Steps1–2do not fit because administered drug precedes and causally changes the weight-loss response. Step3requires prevention/delay on removal, initiation on engagement and rate limitation; retatrutide-specific withdrawal and rate limitation have not all been demonstrated. Step4requiredness is not shown because lifestyle and other drugs can reduce weight. Step5therefore applies to maintenance/modification of the upstream obesity trajectory; this mandatory coarse role label does not assert that drug-caused weight loss is merely correlational.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Decisive work underway", "artifact": "TRIUMPH registrational and Outcomes programme; registered active-comparison studies and outcomes trials could address modern comparator and hard-event boundaries. Published TRIUMPH1/2 results now extend evidence to80weeks; protocol or press release is not counted as completed outcome data.", "justification": "TRIUMPH registrational and Outcomes programme; registered active-comparison studies and outcomes trials could address modern comparator and hard-event boundaries. Published TRIUMPH1/2 results now extend evidence to80weeks; protocol or press release is not counted as completed outcome data." }, "stability": { "value": "Uncertain", "trigger": "Direct modern-comparator results and retatrutide-specific withdrawal/long-term outcomes could improve comparative scope and independence; adverse-event, discontinuation or durability findings could narrow the clinical context. These can move different subclaims in different directions.", "justification": "Direct modern-comparator results and retatrutide-specific withdrawal/long-term outcomes could improve comparative scope and independence; adverse-event, discontinuation or durability findings could narrow the clinical context. These can move different subclaims in different directions." }, "divergence": { "implied_level": null, "implied_level_basis": "Supervised-efficacy publications and online-supply promotion make different propositions; no defensible field-wide implied HSEFletter was measured.", "assessed_level": "Ε", "gap_in_rungs": null, "value": "Contested", "justification": "No survey of competent-reader inferred ladder levels was performed; supply publicity is not a field-wide scientific consensus." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Ε", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over72weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity.", "readout": "Prespecified percent weight change,≥5%responders, objective strength/function and adverse-event/discontinuation outcomes; exposure and intake/energy expenditure separately.", "critical_control": "Comparable dose escalation, verified formulations, matched follow-up/estimands and lifestyle support; independent assessor, missingness sensitivity and both randomized and tolerator populations reported.", "supporting_result": "Greater clinically meaningful weight/function benefit under comparable conditions plus intervention-sensitive retatrutide maintenance under an independently assessed withdrawal contrast would strengthen comparative and causal-line claims.", "falsifying_result": "No matched active advantage, poorer tolerated effectiveness or lack of maintenance sensitivity would narrowSC3or maintenance inference while preserving any confirmed placebo-controlled initiation benefit." } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Direct matched retatrutide versus modern obesity-dose semaglutide/tirzepatide superiority with comparable estimands and durability.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Retatrutide-specific withdrawal/rechallenge and long-term weight/function maintenance rather than class extrapolation.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Human contribution of each receptor at measured therapeutic exposure, including energy expenditure and intake partition.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Hard cardiovascular/renal outcomes and longer safety follow-up; surrogate lipid and inflammation analyses are insufficient.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Muscle strength/function and clinically important composition outcomes, withDXAmissingness disclosed.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Independent identified retatrutide supply-batch quality and product-linked clinical evidence; no assay result from semaglutide characterizes everyretatrutide vial.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-12", "reviewer": "Codex", "evidence_base_note": "60 primary reports; literature cutoff 2026-10-12; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained atΕwithout inventing independence or unreachable-ladder rules." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained atΕwithout inventing independence or unreachable-ladder rules." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained atΕwithout inventing independence or unreachable-ladder rules." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained atΕwithout inventing independence or unreachable-ladder rules." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained atΕwithout inventing independence or unreachable-ladder rules." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 60, "claims_total": 65, "claims_verified": 65, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 60, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "A338-adult randomized placebo trial shows dose-related retatrutide weight loss through48weeks, with high-dose responder rates exceeding the registered5% benchmark. Placebo efficacy is not superiority to semaglutide or tirzepatide; adverse GI events and heart-rate changes remain relevant.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "Retatrutide reduces DXA fat mass in a randomized T2D phase2 substudy, with positive higher-dose contrasts. Only103participants completed treatment and both DXA scans; lean mass is not muscle strength, and this shares NCT04867785 rather than supplying a new trial.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "Randomized phase2 appetite analysis finds higher-dose hunger and disinhibition reductions and modest eating-inventory correlations with weight change. Satiety/fullness and aggregate appetite-to-weight correlations are often null; self-report correlations do not isolate receptor mediation; same phase2 trial.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph2, 4:RESULTS:paragraph0, 4:RESULTS:paragraph2, 4:RESULTS:paragraph5, 4:RESULTS:paragraph7, 4:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "TRANSCEND-T2D-1 randomizes537adults and reports treatment-regimen weight loss of11.5–15.3% versus2.6%placebo at40weeks. Primary endpoint is HbA1c; entry BMI≥23includes participants outside the registered obesity/overweight scope, so whole-cohort means are corroboration with a population limitation.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "TRIUMPH-2 shows substantial placebo-adjusted weight loss in1152adults with BMI≥27 and T2D using multiple-imputation treatment-regimen analyses. The80-week endpoint extends beyond the registered24–72-week horizon; no modern active comparator, and dysesthesia/hypotension/discontinuations qualify safety.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "Randomized double-dummy phase2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide1.5mg through36weeks. Dulaglutide1.5mg is not modern obesity-dose semaglutide or tirzepatide; six inadvertent enrollments excluded from efficacy analyses; lower dose weak/null.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "Original phase2 metabolomics secondary analyses detect fatty-acid oxidation and insulin-resistance clusters associated with retatrutide. Mediation models and metabolic proxies do not establish human receptor-specific energy-expenditure causality; shares both phase2 datasets.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "Original phase2 post-hoc lipid/lipoprotein analyses show treatment-associated shifts in two populations; inflammation changes differ by diabetes status. Post-discontinuation/rescue samples excluded; no hard cardiovascular outcomes, and lipid/inflammation changes are not independent new causal trials.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Material and Methods:paragraph0, 1:Material and Methods:paragraph2, 1:Material and Methods:paragraph3, 2:Results:paragraph0, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "Propensity-matched dispensing/EHR cohort associates tirzepatide with greater on-treatment weight loss than semaglutide. Selection, dosing, discontinuation and missing weight measurements remain; neither arm receives retatrutide.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "Bucher indirect reanalysis compares SURMOUNT-2 and STEP2 and estimates larger weight reduction with tirzepatide. Inter-trial comparability assumptions do not create randomized head-to-head allocation; same underlying studies as40321113; no retatrutide arm.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "Original indirect reanalysis estimates larger tirzepatide weight reductions than semaglutide, with sensitivity analyses. Not an independent RCT despite indexed publication tags; shares SURMOUNT-2 and STEP2 and does not test retatrutide superiority.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "SURMOUNT-5 subgroup with baseline Japanese obesity-disease criteria preserves tirzepatide advantage over semaglutide. Subset of the same trial, not an extra causal line; global enrollment criteria and no retatrutide limit transfer.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "Retrospective obesity cohort associates tirzepatide with larger weight reduction than semaglutide/liraglutide. Nonrandom treatment allocation and treatment persistence selection; cannot rank retatrutide or measure receptor necessity.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "Original receptor signaling and primary-islet experiments show imbalanced GIPR/GLP1R engagement and GLP1R signaling bias for tirzepatide. This dual agonist demonstrates an alternative receptor architecture; occupancy estimates are not measured retatrutide target engagement in patients.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "Tirzepatide phase1 human and pair-fed mouse studies find fat oxidation and appetite effects, but metabolic adaptation effects differ between species. Human lack of adaptation effect challenges simple mouse-to-human energy-expenditure transfer; different drug cannot falsify retatrutide weight efficacy.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "Original human adipocyte/mouse assays show context-dependent GIPR effects on glucose uptake, lipid release and clearance. Tirzepatide/GIPR agonists, not clinical retatrutide; linked correction PMID38945123 is attached and revised numerical details were not available.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "Glp1r-null mice and selective GIP agonism separate a weight-independent insulin-sensitization component of tirzepatide. Glucose disposal and BCAA changes do not demonstrate human weight loss or the necessity of retatrutide glucagon activity.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "Optimized triagonist16 outperforms equimolar tirzepatide in DIO mice and raises indirect-calorimetry energy expenditure with similar intake suppression. Compound16 is not retatrutide; male-mouse exposures and whole-body calorimetry do not establish clinical superiority or partition every receptor.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph9, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "Vgat-Gipr deletion removes enhanced weight/intake reduction from long-acting GIP and a dual coagonist in DIO male mice. Different peptide and cell-specific developmental knockout do not directly establish retatrutide human mechanism or all GIPR cell populations.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "Original dual-incretin development demonstrates metabolic effects across rodents, primates and early humans. This alternative GIP/GLP1 architecture shows triple agonism is not necessary for weight benefit; no matched human retatrutide comparison.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "Human-islet receptor antagonism shows tirzepatide insulin secretion depends on both incretin receptors, while mouse potency favors GLP1R. Insulin secretion is not clinical bodyweight reduction; species-specific potency cautions against simple receptor transfer to retatrutide.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "Fiber photometry and incretin perturbations show pharmacological analogs inhibit AgRP hunger neurons, with endogenous GIP specificity. Neural activity and short-term intake do not alone prove the retatrutide clinical mechanism or contribution of glucagon.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "Cryo-EM structures resolve multiplexed receptor binding by tirzepatide and peptide20. Reconstituted engineered complexes are not living-patient occupancy or proof that three components jointly cause clinical superiority.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "IUB447 knockout/antagonist assays identify GLP1R–Gαq–TRPM5-centered insulin secretion; individual Gipr/Gcgr removal leaves GSIS enhancement. Different triagonist and glucose endpoint cannot refute retatrutide weight loss; shows triagonist label need not imply equal receptor necessity for every outcome.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "Whole-body and GABAergic GIPR knockout increase GLP1-alone weight effects while eliminating dual-agonist enhancement and anti-aversion. Both agonism and removal can yield benefit; cell/agent-specific mechanism, not proof all GIPR strategies act identically.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "Original33-patient surgical tissue assays report incretin/glucagon receptor expression in epicardial fat. Expression and transcript associations are presence evidence, not functional drug engagement, weight causality or cardiovascular protection.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "Lepr-Gipr deletion removes enhanced glycemic effects of dual agonism but leaves bodyweight and food-intake effects intact. Cell-specific null maps receptor-function boundaries; glucose and weight outcomes are different, and retatrutide was not tested.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "STEP1 extension reports substantial regain after withdrawal of semaglutide and lifestyle support. Exploratory selected extension with joint lifestyle withdrawal; same STEP1 trial and different drug, not retatrutide withdrawal proof.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "STEP4 randomized continuation versus withdrawal causally separates semaglutide weight maintenance in run-in tolerators. Enrollment to randomization selects tolerated exposure; this comparative class result cannot establish retatrutide off-treatment durability.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "Original STEP1/4 exploratory analyses report cardiometabolic changes that worsen after semaglutide withdrawal. Shared study participants and surrogate risk metrics cannot supply independent retatrutide efficacy or cardiovascular benefit.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "STEP1/4/5 post-hoc risk-score analyses track improvements with semaglutide and deterioration after withdrawal. Estimated10-year risk is not observed10-year diabetes incidence; secondary analysis shares trials and excludes retatrutide.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "STEP1 randomizes1961adults and demonstrates semaglutide weight loss beyond lifestyle/placebo at68weeks. Different molecule and trial population; percentages must not be ranked as a randomized retatrutide comparison.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "STEPUP directly compares semaglutide7.2mg with2.4mg/placebo and reports additional weight loss plus more dysesthesia. No retatrutide arm; higher-dose comparator benefits and adverse events change the comparison question.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "STEP9 randomizes407adults with kneeOA/obesity and improves weight and pain with semaglutide. Disease-specific pain scales and population cannot be directly compared with TRIUMPH subgroup outcomes or establish triple receptor necessity.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "STEP2 placebo-controlled diabetes/obesity trial establishes semaglutide weight loss and5%responder benefits. Diabetes modifies population/estimand, and no retatrutide arm; parent dataset for indirect comparison analyses.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "STEP5 demonstrates sustained semaglutide weight benefit at104weeks. Longer treatment efficacy is not off-treatment durability or retatrutide efficacy; predominantly White/female participants.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "STEP3 shows semaglutide adds weight benefit to intensive behavioral therapy and initial low-calorie diet. Co-intervention differs from other obesity trials, precluding naive cross-trial superiority; no retatrutide arm.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "STEP8 randomized active-drug comparison establishes greater semaglutide than liraglutide weight loss. Active comparison is open-label and titration/tolerability rules differ; neither regimen is retatrutide.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "STEP-HFpEF improves symptoms, walk distance and weight with semaglutide in obesity-relatedHFpEF. Specific heart-failure population and endpoint do not establish retatrutide event prevention or clinical superiority.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "STEP-HFpEF-DM shows semaglutide weight and functional benefits in obesity-relatedHFpEF withT2D. Different clinical syndrome and molecule; cannot loan hard cardiac or functional outcomes to retatrutide.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "STEP10 establishes semaglutide weight reduction and normoglycemia in baseline prediabetes. Normoglycemia endpoint/duration is not long-term disease prevention or evidence of retatrutide superiority.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "STEPUP-T2D shows semaglutide7.2mg beats placebo for weight loss, with more dysesthesia. No retatrutide arm and linked erratum PMID41932351 limits unaudited detailed numerics.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "STEP1–4 secondary analyses find semaglutide weight loss both with and without GI events; mediation estimates little GI-mediated loss. GI mediation is model-dependent, not randomized nausea separation; shared parent trials and not retatrutide.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "SURMOUNT1 extended randomized treatment reports sustained tirzepatide weight loss and lower observed diabetes progression over176weeks. Same SURMOUNT1 study as72-week report, restricted baseline prediabetes cohort; benefit cannot be transferred to retatrutide.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "SURMOUNT1 establishes tirzepatide weight loss and responder benefits beyond placebo at72weeks. No retatrutide and different dose schedules, estimands and populations from triple-agonist trials.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "SURMOUNT4 randomized withdrawal shows weight regain after switch to placebo and maintenance with continued tirzepatide. Open-label run-in selects completers/tolerators, and class withdrawal does not establish retatrutide withdrawal dynamics.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "SURMOUNT5 directly randomizes tirzepatide versus semaglutide and demonstrates greater tirzepatide weight reduction at72weeks. Open-label active comparison and dose tolerability differ; this establishes their relationship, not retatrutide superiority.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "SURMOUNT-CN demonstrates placebo-controlled tirzepatide weight loss in Chinese adults at52weeks. Different drug/regionalBMI criteria, and linked erratum PMID38913535 attaches to parent not separate evidence.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "SURMOUNT-MAINTAIN randomizes continued/reduced-dose tirzepatide versus withdrawal and finds maintenance advantages. Rescue after substantial regain and modified estimand complicate raw comparisons; linked erratum PMID42242249; not retatrutide.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "SURMOUNT3 shows tirzepatide adds further loss after a successful intensive lifestyle run-in. Baseline-to-randomization responders are prespecified selected cohort, not all entrants; linked correction PMID38409593; no retatrutide.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "SURMOUNT-J shows placebo-controlled tirzepatide weight benefits in Japanese obesity-disease patients. ModifiedITT excludes a site and nationaleligibility differs; no retatrutide; generalization remains endpoint/population-specific.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "Original three NN1177 dual-agonist phase1 trials show weight loss but safety signals stop development. Different peptide and short trials; linked erratum PMID39245214; efficacy alone does not guarantee safety of polyagonism.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "JNJ64565111 dual GLP1/glucagon trial reduces weight versus placebo with greater GI events. No GIP component yet weight benefit, so triple agonism is not necessary for weight loss in general; different molecule does not rank retatrutide.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "JNJ64565111 lowers weight in T2D/obesity but does not improve HbA1c and raises some glucose measures. Weight and glycemic benefit separate; short different-agent trial cannot falsify retatrutide's positive clinical results.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "TRIUMPH1 randomizes2339adults withoutdiabetes and reports treatment-regimen weight reductions up to25.0% versus3.9%placebo at80weeks. Beyond registered24–72-week horizon; no active modern comparator; originalabstractcontains an inconsistentOSA sign so that subgroupnumber is not repeated.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals. Single-dose early human study is not24–72-week efficacy or receptor-component necessity in humans; compound-specific mechanism needs matched counterfactuals.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C57", "text": "Original semaglutide test-purchase study finds mislabeled quantities, measured purity of 7.7-14.37% against a 99% label claim, and endotoxin detected in all three delivered vials, plus nondelivery scams. The highest-risk small-vendor sample, assay purity interpretation and the upper-bound form of two of the three endotoxin values all matter; this is not retatrutide testing or clinical population incidence.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph7, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph21, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C58", "text": "Analytical follow-on semaglutide/liraglutide comparisons detect altered impurities, content, dissolution and predicted immunogenicity/stability. In-silico epitopes and quality changes do not demonstrate clinical harms; commercially available follow-ons are not all online retatrutide vials.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C59", "text": "Twenty untrained adults performing simulated grey-market semaglutide tasks make dosing/injection-process errors. Simulation is not actual retatrutide use or measured infection/adverse-event incidence; no instructions reproduced in the review.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C60", "text": "Glucagon agonist effects on mouse weight/energy expenditure depend on FGF21 deletion, with acute human FGF21 response to glucagon. Single agonist/mouse knockout and acute biomarker response do not establish human retatrutide glucagon necessity; hyperglycemia can coexist with weight loss.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:RESEARCH DESIGN AND METHODS:paragraph0, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13, 1:RESULTS:paragraph15, 1:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC1", "text": "Functional receptor assays and LY3437943 mouse pharmacology support in vivo engagement and cross the first perturbation threshold in that experimental setting. Human trial exposure and pharmacokinetics support plausibility, but receptor-by-receptor occupancy, energy expenditure and necessity at therapeutic human exposures are not directly partitioned. This is not a claim of demonstrated human three-receptor necessity.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 3, 7, 8, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30, 43, 52, 53, 54, 56, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "Randomized trials show clinically meaningful weight loss in prespecified adult settings, including the48-week obesity phase2 study and36-week diabetes phase2 study. Low doses do not uniformly exceed placebo, and doses and eligibility remain part of context. Additional40-week diabetes phase3 evidence and80-week TRIUMPH results corroborate the effect but have distinct enrollment/horizon qualifications. Replicated same-modality RCTs raise confidence; comparator studies and secondary analyses do not create independent retatrutide causal lines.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 8, 55, 56 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide1.5mg in its specific diabetes phase2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 2, 5, 6, 9, 10, 11, 12, 13, 15, 18, 20, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "No directly examined product-linked retatrutide testing plus clinical evidence establishes that online research vials reproduce trial quality, efficacy and safety. Semaglutide/liraglutide analytical testing and a simulated preparation study identify relevant failure modes but cannot characterize every retatrutide vial. This positive equivalence proposition remains speculative; lack of approval and lack of evidence are not direct measurements of every product.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 57, 58, 59 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "Retatrutide causes substantial weight loss in supervised trials; superiority to modern obesity drugs and equivalence of online research vials remain unestablished in this review.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 6, 4, 5, 55, 47, 57 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37366315", "doi": "10.1056/NEJMoa2301972", "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04881760", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2", "CSC3", "CH" ] }, { "n": 2, "citation": "Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40609566", "doi": "10.1016/S2213-8587(25)00092-0", "url": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2", "CSC3" ] }, { "n": 3, "citation": "Kanu C, Boye KS, Poon JL et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, obesity & metabolism. 2025.", "tier": "A", "kind": "rct", "pmid": "40916752", "doi": "10.1111/dom.70097", "url": "https://pubmed.ncbi.nlm.nih.gov/40916752/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph2, 4:RESULTS:paragraph0, 4:RESULTS:paragraph2, 4:RESULTS:paragraph5, 4:RESULTS:paragraph7, 4:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC2" ] }, { "n": 4, "citation": "Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "42250575", "doi": "10.1016/S0140-6736(26)00967-0", "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT06354660", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2", "CH" ] }, { "n": 5, "citation": "Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "42810372", "doi": "10.1016/S0140-6736(26)01861-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT05929079", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC3", "CH" ] }, { "n": 6, "citation": "Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023.", "tier": "A", "kind": "rct", "pmid": "37385280", "doi": "10.1016/S0140-6736(23)01053-X", "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC2", "CSC3", "CH" ] }, { "n": 7, "citation": "Pearson MJ, Willency JA, Lin Y et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2026.", "tier": "A", "kind": "primary", "pmid": "42135195", "doi": "10.1210/clinem/dgag201", "url": "https://pubmed.ncbi.nlm.nih.gov/42135195/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-PHASE2-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1" ] }, { "n": 8, "citation": "Ruotolo G, Harris C, Lin Y et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, obesity & metabolism. 2026.", "tier": "A", "kind": "rct", "pmid": "42608321", "doi": "10.1111/dom.71200", "url": "https://pubmed.ncbi.nlm.nih.gov/42608321/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-PHASE2-POOLED", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Material and Methods:paragraph0, 1:Material and Methods:paragraph2, 1:Material and Methods:paragraph3, 2:Results:paragraph0, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1", "CSC2" ] }, { "n": 9, "citation": "Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024.", "tier": "A", "kind": "primary", "pmid": "38976257", "doi": "10.1001/jamainternmed.2024.2525", "url": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38976257", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC3" ] }, { "n": 10, "citation": "Ciudin A, Johansson E, Zimner-Rapuch S et al. Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2025.", "tier": "A", "kind": "primary", "pmid": "40537987", "doi": "10.1111/dom.16508", "url": "https://pubmed.ncbi.nlm.nih.gov/40537987/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT2-STEP2-ITC", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC3" ] }, { "n": 11, "citation": "Hankosky ER, He X, Malik R et al. Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, obesity & metabolism. 2025.", "tier": "A", "kind": "primary", "pmid": "40321113", "doi": "10.1111/dom.16401", "url": "https://pubmed.ncbi.nlm.nih.gov/40321113/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT2-STEP2-ITC", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC3" ] }, { "n": 12, "citation": "Kitamoto T, Yoshino M, Shingaki T et al. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. Current medical research and opinion. 2026.", "tier": "A", "kind": "rct", "pmid": "42434924", "doi": "10.1080/03007995.2026.2695047", "url": "https://pubmed.ncbi.nlm.nih.gov/42434924/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT5-NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC3" ] }, { "n": 13, "citation": "Cetiner S. Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2026.", "tier": "A", "kind": "primary", "pmid": "41938643", "doi": "10.2147/DMSO.S594898", "url": "https://pubmed.ncbi.nlm.nih.gov/41938643/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41938643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC3" ] }, { "n": 14, "citation": "Willard FS, Douros JD, Gabe MB et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight. 2020.", "tier": "A", "kind": "primary", "pmid": "32730231", "doi": "10.1172/jci.insight.140532", "url": "https://pubmed.ncbi.nlm.nih.gov/32730231/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32730231", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC1" ] }, { "n": 15, "citation": "Ravussin E, Sanchez-Delgado G, Martin CK et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell metabolism. 2025.", "tier": "A", "kind": "rct", "pmid": "40203836", "doi": "10.1016/j.cmet.2025.03.011", "url": "https://pubmed.ncbi.nlm.nih.gov/40203836/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40203836", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC3" ] }, { "n": 16, "citation": "Regmi A, Aihara E, Christe ME et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell metabolism. 2024.", "tier": "A", "kind": "primary", "pmid": "38878772", "doi": "10.1016/j.cmet.2024.05.010", "url": "https://pubmed.ncbi.nlm.nih.gov/38878772/", "status_flags": [ "ErratumIn: PMID38945123" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38878772", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC1" ] }, { "n": 17, "citation": "Samms RJ, Christe ME, Collins KA et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. The Journal of clinical investigation. 2021.", "tier": "A", "kind": "primary", "pmid": "34003802", "doi": "10.1172/JCI146353", "url": "https://pubmed.ncbi.nlm.nih.gov/34003802/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34003802", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1" ] }, { "n": 18, "citation": "Knerr PJ, Mowery SA, Douros JD et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular metabolism. 2022.", "tier": "A", "kind": "primary", "pmid": "35809773", "doi": "10.1016/j.molmet.2022.101533", "url": "https://pubmed.ncbi.nlm.nih.gov/35809773/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35809773", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph9, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC1", "CSC3" ] }, { "n": 19, "citation": "Liskiewicz A, Khalil A, Liskiewicz D et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature metabolism. 2023.", "tier": "A", "kind": "primary", "pmid": "37946085", "doi": "10.1038/s42255-023-00931-7", "url": "https://pubmed.ncbi.nlm.nih.gov/37946085/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37946085", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1" ] }, { "n": 20, "citation": "Finan B, Ma T, Ottaway N et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science translational medicine. 2013.", "tier": "A", "kind": "rct", "pmid": "24174327", "doi": "10.1126/scitranslmed.3007218", "url": "https://pubmed.ncbi.nlm.nih.gov/24174327/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24174327", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1", "CSC3" ] }, { "n": 21, "citation": "El K, Douros JD, Willard FS et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature metabolism. 2023.", "tier": "A", "kind": "primary", "pmid": "37277609", "doi": "10.1038/s42255-023-00811-0", "url": "https://pubmed.ncbi.nlm.nih.gov/37277609/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37277609", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC1" ] }, { "n": 22, "citation": "McMorrow HE, Cohen AB, Lorch CM et al. Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice. The Journal of clinical investigation. 2025.", "tier": "A", "kind": "primary", "pmid": "40857106", "doi": "10.1172/JCI186652", "url": "https://pubmed.ncbi.nlm.nih.gov/40857106/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40857106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1" ] }, { "n": 23, "citation": "Zhao F, Zhou Q, Cong Z et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nature communications. 2022.", "tier": "A", "kind": "primary", "pmid": "35217653", "doi": "10.1038/s41467-022-28683-0", "url": "https://pubmed.ncbi.nlm.nih.gov/35217653/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35217653", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC1" ] }, { "n": 24, "citation": "Schreier PCF, Beyerle P, Boulassel S et al. GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice. Diabetologia. 2025.", "tier": "A", "kind": "primary", "pmid": "40924112", "doi": "10.1007/s00125-025-06525-0", "url": "https://pubmed.ncbi.nlm.nih.gov/40924112/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40924112", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1" ] }, { "n": 25, "citation": "Wean J, Kowalsky AH, Laker R et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Molecular metabolism. 2025.", "tier": "A", "kind": "primary", "pmid": "39612941", "doi": "10.1016/j.molmet.2024.102074", "url": "https://pubmed.ncbi.nlm.nih.gov/39612941/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39612941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC1" ] }, { "n": 26, "citation": "Malavazos AE, Iacobellis G, Dozio E et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. European journal of preventive cardiology. 2023.", "tier": "A", "kind": "primary", "pmid": "36799940", "doi": "10.1093/eurjpc/zwad050", "url": "https://pubmed.ncbi.nlm.nih.gov/36799940/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36799940", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1" ] }, { "n": 27, "citation": "Akindehin S, Liskiewicz A, Liskiewicz D et al. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular metabolism. 2024.", "tier": "A", "kind": "primary", "pmid": "38492844", "doi": "10.1016/j.molmet.2024.101915", "url": "https://pubmed.ncbi.nlm.nih.gov/38492844/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38492844", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC1" ] }, { "n": 28, "citation": "Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022.", "tier": "A", "kind": "rct", "pmid": "35441470", "doi": "10.1111/dom.14725", "url": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC3" ] }, { "n": 29, "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "tier": "A", "kind": "rct", "pmid": "33755728", "doi": "10.1001/jama.2021.3224", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP4-NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC3" ] }, { "n": 30, "citation": "Kosiborod MN, Bhatta M, Davies M et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, obesity & metabolism. 2023.", "tier": "A", "kind": "primary", "pmid": "36200477", "doi": "10.1111/dom.14890", "url": "https://pubmed.ncbi.nlm.nih.gov/36200477/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC1", "CSC3" ] }, { "n": 31, "citation": "Wilkinson L, Holst-Hansen T, Laursen PN et al. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring, Md.). 2023.", "tier": "A", "kind": "rct", "pmid": "37605636", "doi": "10.1002/oby.23842", "url": "https://pubmed.ncbi.nlm.nih.gov/37605636/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-4-5-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC3" ] }, { "n": 32, "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "33567185", "doi": "10.1056/NEJMoa2032183", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC3" ] }, { "n": 33, "citation": "Wharton S, Freitas P, Hjelmesæth J et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40961952", "doi": "10.1016/S2213-8587(25)00226-8", "url": "https://pubmed.ncbi.nlm.nih.gov/40961952/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961952", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC3" ] }, { "n": 34, "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "39476339", "doi": "10.1056/NEJMoa2403664", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39476339", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC3" ] }, { "n": 35, "citation": "Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021.", "tier": "A", "kind": "rct", "pmid": "33667417", "doi": "10.1016/S0140-6736(21)00213-0", "url": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP2-NCT03552757", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC3" ] }, { "n": 36, "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "36216945", "doi": "10.1038/s41591-022-02026-4", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36216945", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC3" ] }, { "n": 37, "citation": "Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.", "tier": "A", "kind": "rct", "pmid": "33625476", "doi": "10.1001/jama.2021.1831", "url": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33625476", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC3" ] }, { "n": 38, "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "tier": "A", "kind": "rct", "pmid": "35015037", "doi": "10.1001/jama.2021.23619", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35015037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC3" ] }, { "n": 39, "citation": "Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37622681", "doi": "10.1056/NEJMoa2306963", "url": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37622681", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC3" ] }, { "n": 40, "citation": "Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38587233", "doi": "10.1056/NEJMoa2313917", "url": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38587233", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC3" ] }, { "n": 41, "citation": "McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024.", "tier": "A", "kind": "rct", "pmid": "39089293", "doi": "10.1016/S2213-8587(24)00182-7", "url": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39089293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC3" ] }, { "n": 42, "citation": "Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40961953", "doi": "10.1016/S2213-8587(25)00225-6", "url": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "status_flags": [ "ErratumIn: PMID41932351" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961953", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC3" ] }, { "n": 43, "citation": "Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022.", "tier": "A", "kind": "rct", "pmid": "34514682", "doi": "10.1111/dom.14551", "url": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-2-3-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1", "CSC3" ] }, { "n": 44, "citation": "Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39536238", "doi": "10.1056/NEJMoa2410819", "url": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT1-NCT04184622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC3" ] }, { "n": 45, "citation": "Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "35658024", "doi": "10.1056/NEJMoa2206038", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT1-NCT04184622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC3" ] }, { "n": 46, "citation": "Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.", "tier": "A", "kind": "rct", "pmid": "38078870", "doi": "10.1001/jama.2023.24945", "url": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT4-NCT04660643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC3" ] }, { "n": 47, "citation": "Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025.", "tier": "A", "kind": "primary", "pmid": "40353578", "doi": "10.1056/NEJMoa2416394", "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SURMOUNT5-NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC3", "CH" ] }, { "n": 48, "citation": "Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.", "tier": "A", "kind": "rct", "pmid": "38819983", "doi": "10.1001/jama.2024.9217", "url": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "status_flags": [ "ErratumIn: PMID38913535" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38819983", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC3" ] }, { "n": 49, "citation": "Horn DB, Aronne LJ, Wharton S et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "42119587", "doi": "10.1016/S0140-6736(26)00656-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42119587/", "status_flags": [ "ErratumIn: PMID42242249" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42119587", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC3" ] }, { "n": 50, "citation": "Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37840095", "doi": "10.1038/s41591-023-02597-w", "url": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "status_flags": [ "ErratumIn: PMID38409593" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37840095", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC3" ] }, { "n": 51, "citation": "Kadowaki T, Kiyosue A, Shingaki T et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40031941", "doi": "10.1016/S2213-8587(24)00377-2", "url": "https://pubmed.ncbi.nlm.nih.gov/40031941/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40031941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC3" ] }, { "n": 52, "citation": "Friedrichsen MH, Endahl L, Kreiner FF et al. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. Molecular metabolism. 2023.", "tier": "A", "kind": "rct", "pmid": "37690519", "doi": "10.1016/j.molmet.2023.101801", "url": "https://pubmed.ncbi.nlm.nih.gov/37690519/", "status_flags": [ "ErratumIn: PMID39245214" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37690519", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC1", "CSC3" ] }, { "n": 53, "citation": "Alba M, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clinical obesity. 2021.", "tier": "A", "kind": "rct", "pmid": "33475255", "doi": "10.1111/cob.12432", "url": "https://pubmed.ncbi.nlm.nih.gov/33475255/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33475255", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC1", "CSC3" ] }, { "n": 54, "citation": "Di Prospero NA, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clinical obesity. 2021.", "tier": "A", "kind": "rct", "pmid": "33475251", "doi": "10.1111/cob.12433", "url": "https://pubmed.ncbi.nlm.nih.gov/33475251/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33475251", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC1", "CSC3" ] }, { "n": 55, "citation": "Jastreboff AM, Kaplan LM, Davies MJ et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England journal of medicine. 2026.", "tier": "A", "kind": "rct", "pmid": "42814954", "doi": "10.1056/NEJMoa2604169", "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RETAT-NCT05929066", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC2", "CSC3", "CH" ] }, { "n": 56, "citation": "Coskun T, Urva S, Roell WC et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism. 2022.", "tier": "A", "kind": "primary", "pmid": "35985340", "doi": "10.1016/j.cmet.2022.07.013", "url": "https://pubmed.ncbi.nlm.nih.gov/35985340/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35985340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC1", "CSC2" ] }, { "n": 57, "citation": "Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024.", "tier": "A", "kind": "primary", "pmid": "39509151", "doi": "10.2196/65440", "url": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMAGLUTIDE-ONLINE-PURCHASES-2023", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph7, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph21, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC4", "CH" ] }, { "n": 58, "citation": "Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024.", "tier": "A", "kind": "primary", "pmid": "39379664", "doi": "10.1007/s11095-024-03771-6", "url": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39379664", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC4" ] }, { "n": 59, "citation": "Sedensky A, Nuzi K, Nolan L et al. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription. Public health reports (Washington, D.C. : 1974). 2026.", "tier": "A", "kind": "primary", "pmid": "42541373", "doi": "10.1177/00333549261464876", "url": "https://pubmed.ncbi.nlm.nih.gov/42541373/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42541373", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC4" ] }, { "n": 60, "citation": "Habegger KM, Stemmer K, Cheng C et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013.", "tier": "A", "kind": "rct", "pmid": "23305646", "doi": "10.2337/db12-1116", "url": "https://pubmed.ncbi.nlm.nih.gov/23305646/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23305646", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:RESEARCH DESIGN AND METHODS:paragraph0, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13, 1:RESULTS:paragraph15, 1:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC1" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "All assigned models remain belowΖ. Retatrutide placebo/active-dose trials are replications of a pharmacological intervention modality; one common formulation/exposure or intervention-associated-bias failure could affect them. Secondary reports share parent trials. Rodent receptor perturbations and class-drug withdrawal inform alternatives but do not independently prove the exact registered human retatrutide claim. No different-lab or different-trial-count shortcut is used." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately." } ], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/retatrutide-clinical-trial-analysis/11vWq7mLT7yQ4fV1S4bsUw/" ], "query_record_note": "Exact visible question/response retained privately in raw browser receipt.", "primary_comparison_count": 9, "primary_comparisons": [ { "pmid": "37366315", "doi": "10.1056/NEJMoa2301972", "source_type": "primary study report", "study_group": "RETAT-NCT04881760", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus identifies placebo-controlled phase2 weight efficacy and dose/tolerability.", "result_comparison": "Original abstract agrees with338randomized adults,24-week primary and48-week secondary weights and high-dose5%responders. This supports trial efficacy, not a modern active-comparator superiority claim. Fulltrial Methods/supplementwere not fully audited.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "42250575", "doi": "10.1016/S0140-6736(26)00967-0", "source_type": "primary study report", "study_group": "RETAT-NCT06354660", "access_depth": "abstract_metadata", "consensus_aspect": "Provider reports40-week TRANSCEND-T2D-1 phase3 weight results and completion.", "result_comparison": "Original abstract confirms537participants and treatment-regimen weight change−11.5%to−15.3%versus−2.6%placebo. Primary endpointisHbA1c and entryBMI≥23; whole-cohort weights do not exactly estimate the preregistered obesity/overweight subset.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "42814954", "doi": "10.1056/NEJMoa2604169", "source_type": "primary study report", "study_group": "RETAT-NCT05929066", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus does not retrieve the named2026TRIUMPH1results and instead cites the2025designpaper.", "result_comparison": "Original PMID42814954 confirms peer-reviewed29September2026results,2339randomizedparticipants and80-week treatment-regimen weights up to−25.0%versus−3.9%placebo. Provider corpus omission is not absenceofpublication.80weeks is longer-horizon corroboration beyond our registered24–72weeks. IndexedOSA sign inconsistency is flagged without repeatingthatnumber.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42814954/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-56-62-6000.json" ], "body_receipts": [] }, { "pmid": "42810372", "doi": "10.1016/S0140-6736(26)01861-1", "source_type": "primary study report", "study_group": "RETAT-NCT05929079", "access_depth": "abstract_metadata", "consensus_aspect": "Provider similarly lacks indexedTRIUMPH2resulttext.", "result_comparison": "Original PMID42810372 confirms1152randomized adults withBMI≥27andT2D, multiple-imputation treatment-regimen weight results at80weeks and tolerability signals. This resultisavailablebeforecutoff; provider gap cannotbe called a researchgap.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "37385280", "doi": "10.1016/S0140-6736(23)01053-X", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus distinguishes older dulaglutide active comparison from obesity-standard comparator evidence.", "result_comparison": "Original randomized double-dummy phase2 report confirms36-week retatrutideweight loss beyond dulaglutide1.5mg atdoses≥4mg, but cannot establish superiorityoverobesity-dose semaglutide/tirzepatide.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "40916752", "doi": "10.1111/dom.70097", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "full_text_partial", "consensus_aspect": "Provider suggests appetite modification contributes to weight loss.", "result_comparison": "Selected original Methods/Results retain self-reportedhigher-dose hunger effects, but satiety/fullness and aggregate appetite-to-weight correlations are oftennull. These are samephase2participants, not a newtrial or proof of receptor-specific mediation.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40916752/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\40916752-s1-p0-2.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\40916752-s4-p0-2-5-7-14.json" ] }, { "pmid": "42608321", "doi": "10.1111/dom.71200", "source_type": "primary study report", "study_group": "RETAT-PHASE2-POOLED", "access_depth": "full_text_partial", "consensus_aspect": "Consensus describes lipid remodeling andmechanistic humanfollow-up.", "result_comparison": "Selected originalbodyconfirms post-hoc phase2analyses and exclusionofpost-discontinuation/rescue samples. Inflammationcontrasts are nonsignificant inT2D but somepositive in non-diabetes. Surrogates are not hardcardiovascularoutcomes or independentclinicalcausallines.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42608321/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\42608321-s1-p0-2-3.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\42608321-s2-p0-12-14.json" ] }, { "pmid": "39509151", "doi": "10.2196/65440", "source_type": "primary study report", "study_group": "SEMAGLUTIDE-ONLINE-PURCHASES-2023", "access_depth": "full_text_partial", "consensus_aspect": "Provider reports no direct retatrutide online-vialquality data initscorpus.", "result_comparison": "Our original class-product testing issemaglutide, notretatrutide, andhighest-risk vendor sampling islimited. Results report upper-bound endotoxinvalues fortwo samples and anelevatedmeasuredvalueforone despiteabstractbroadwording. Suchdataestablishesfailuremodes, not everyretatrutidevialquality.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-56-62-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\39509151-s1-p0-7-11-12.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\39509151-s2-p21-27-28-32.json" ] }, { "pmid": "40609566", "doi": "10.1016/S2213-8587(25)00092-0", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "consensus_aspect": "Provider calls bodycomposition andweight-quality outcomesunderdeveloped.", "result_comparison": "Original2025retatrutideDXAsubstudyexists andshows higher-dosefat-massreduction, but only103completed bothscans. Leanmassproportions do notprove musclefunction or absenceofsarcopenia; thissamephase2trialdoesnotcreateanindependence line.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\consensus-browser-2026-10-12.json", "sha256": "55b772ed5c7cf0f9f3aaecb879cd2571f6ad0637a3d19a4083cc2732d9ffcdb3" } ], "independent_blinded_audit": false, "cutoff": "2026-10-12", "completed_utc": "2026-10-13T06:24:59.082675+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }